Tanespimycin (17-AAG)

Tanespimycin (17-AAG) is an inhibitor of HSP90 used in studies of Apoptosis and Autophagy. In practice, this places the compound in experiments that measure caspase-associated cell-death signaling and survival decisions and autophagic flux, lysosomal turnover, and stress adaptation in apoptosis, autophagy, and cancer models.

By inhibiting HSP90, Tanespimycin (17-AAG) can be used to examine caspase-associated cell-death signaling and survival decisions and autophagic flux, lysosomal turnover, and stress adaptation. This context is compatible with apoptosis, viability, and caspase-readout assays and autophagy-flux, lysosome, and cargo-clearance assays, as well as transcriptional, biochemical, or phenotypic comparisons linked to the annotated pathway state. In apoptosis, autophagy, and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving HSP90
• Pathway perturbation studies connected to Apoptosis and Autophagy
• Concentration-response inhibition and target-dependence studies
• Phenotypic profiling in apoptosis, autophagy, and cancer models

Overall, Tanespimycin (17-AAG) is appropriate when a defined chemical perturbant is needed to connect HSP90 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, autophagy, and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.